Article
Mylan's Tecfidera generic launch jolts Biogen, putting billions at stake
Rating:
0.0
Views:
171
Likes:
1
Library:
1
Despite Biogen's intense effort to defend its big-selling multiple sclerosis drug Tecfidera, Mylan has cleared several legal hurdles to rolling out a copycat—and now it's doing just that. After an early FDA approval for its generic Monday, Mylan said Wednesday it would launch, even at risk of damages if it eventually loses in patent court.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value